Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F. López-Muñoz, C. Álamo, G. Juckel, H.J. Assion.
Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part I: Monoamine oxidase inhibitors.
J Clin Psychopharmacol, 27 (2007), pp. 555-559
[2.]
P. Fangmann, H.J. Assion, G. Juckel, C.A. González, F. López-Muñoz.
Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part II: Tricyclics and tetracyclics.
J Clin Psychopharmacol, 28 (2008), pp. 1-4
[3.]
F. López-Muñoz, C. Álamo.
Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today.
Curr Pharm Des, 15 (2009), pp. 1563-1586
[4.]
C. Álamo, F. López-Muñoz, M.J. Armada.
Agomelatina: un nuevo enfoque farmacológico en el tratamiento de la depresión con traducción clínica.
Psiq Biol, 15 (2008), pp. 125-139
[5.]
C. Álamo, F. López-Muñoz.
New antidepressant drugs: beyond monoaminergic mechanisms.
Curr Pharm Des, 15 (2009), pp. 1559-1562
[6.]
B. Martín-Águeda, F. López-Muñoz, G. Rubio, J.A. Guerra, A. Silva, C. Álamo.
Management of depression in primary care: a survey of general practitioners in Spain.
Gen Hosp Psychiatr, 27 (2005), pp. 305-312
[7.]
C. Álamo, F. López-Muñoz, B. Martín, E. Cuenca.
Biología de la depresión y del tratamiento antidepresivo: mirando al futuro.
Diagnóstico diferencial y racionalización del tratamiento psicofarmacológico, pp. 87-124
[8.]
A. Arendt.
Melatonin and the mammalian pineal gland.
Chapman & May, (1995),
[9.]
M. Ángeles, K. Rodríguez, R. Salgado, C. Escobar.
Anatomía de un reloj (anatomía del sistema circadiano).
Arch Mex Anat (nueva época), 2 (2007), pp. 15-20
[10.]
B. Márquez.
Ritmos circadianos y neurotransmisores: estudios en la corteza prefrontal de la rata. Memoria presentada para optar al grado de Doctor.
Universidad Complutense, (2004),
[11.]
P. Schulz, T. Steimer.
Neurobiology of Circadian Systems.
CNS Drugs, 23 (2009), pp. 3-13
[12.]
R.Y. Moore.
Circadian timing.
Fundamental Neuroscience, pp. 1189-1206
[13.]
T.H. Monk, D.K. Welsh.
The role of chronobiology in sleep disorders medicine.
Sleep Med Rev, 6 (2003), pp. 455-473
[14.]
M.M. Macchi, J.N. Bruce.
Human pineal physiology and functional significance of melatonin.
Front Neuroendocrinol, 25 (2004), pp. 177-195
[16.]
S. Webb, M. Puig-Domingo.
Role of Melatonin in Health and Disease.
Clin Endocrinol, 42 (1995), pp. 221-234
[17.]
B. Guardiola-Lemaitre.
Agonistes et antagonistes des récepteurs mélatoninergiques: effets pharmacologiques et perspectives thérapeutiques.
Ann Pharm Fr, 63 (2005), pp. 385-400
[18.]
R.J. Reiter.
The melatonin rhythm: both a clock and a calendar.
Experientia, 49 (1993), pp. 654-664
[19.]
V. Srinivasan, G.J. Maestroni, D.P. Cardinali, A.I. Esquifino, S.R. Perumal, S.C. Miller.
Melatonin immune functional and aging.
Inmun Ageing, 2 (2005), pp. 17
[20.]
M.L. Dubocovich, M. Markowska.
Functional MT1 and MT2 melatonin receptors in mammals.
Endocrine, 27 (2005), pp. 101-110
[21.]
S.R. Pandi-Perumal, V. Srinivasan, D.P. Cardinali, J.M. Monti.
Could agomelatine be the ideal antidepressant.
Expert Rev Neurotherapeuthics, 6 (2006), pp. 1595-1608
[22.]
L.D. Tan, B. Chen, L.C. Poeggler, L.C. Manchester, R.J. Reiter.
Melatonin: a potent endogenous hydroxyl radical scavenger.
Endocrinol J, 1 (1993), pp. 57-60
[23.]
R.J. Reiter, D.X. Tan, M.P. Terron, L.J. Flores, Z. Czarnocki.
Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions.
Acta Biochim Pol, 54 (2007), pp. 1-9
[24.]
M. Karasek.
Melatonin in humans. Where we are 40 years after its discovery.
Neuroendocrinol Lett, 20 (1999), pp. 179-188
[25.]
C. Pacchierotti, S. Iapichino, L. Bossini, F. Pieraccini, P. Castrogiovanni.
Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry.
Front Neuroendocrinol, 22 (2001), pp. 18-32
[27.]
V. Srinivasan, M. Smits, W. Spence, A.D. Lowe, L. Kayumov, S.R. Pandi-Perumal, et al.
Melatonin in mood disorders.
World J Biol Psychiatry, 7 (2006), pp. 138-151
[28.]
V. Soria, M. Urretavizcaya.
Circadian rhythms and depression.
Actas Esp Psiquiatr, 37 (2009), pp. 222-232
[29.]
F. Peeters, J. Berkhof, P. Delespaul, J. Rottenberg, N.A. Nicholson.
Diurnal mood variation in major depressive disorder.
Emotion, 6 (2006), pp. 383-391
[30.]
R. Armitage.
Sleep and circadian rhythms in mood disorders.
Acta Psychiatr Scand Suppl, 433 (2007), pp. 104-115
[31.]
M.M. Ohayon.
Epidemiology of circadian rhythm disorders in depression.
Medicographia, 29 (2007), pp. 10-16
[32.]
D. Nutt, S. Wilson, L. Paterson.
Sleep disorders as core symptoms of depression.
Dialogues Clin Neurosci, 10 (2008), pp. 329-336
[33.]
J.M. Azorín, A. Kaladjian.
Depression et rythmes circadiens.
L’Encephale, 35 (2009), pp. S68-S71
[34.]
P. Linkowski, J. Mendlewicz, M. Kerkhofs, R. Leclercq, J. Golstein, M. Brasseur, et al.
24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment.
J Clin Endocrinol Metab, 65 (1987), pp. 141-152
[35.]
B. Claustrat, G. Chazot, J. Brun, D. Jordan, G. Sassolas.
A chronobiological study of melatonin and cortisol secretion in depressed subjects: Plasma melatonin a biological marker in major depression.
Biol Psychiatry, 19 (1984), pp. 1215-1228
[36.]
M. Crasson, S. Kjiri, A. Colin, K. Kjiri, M. L’Hermite-Baleriaux, M. Ansseau, et al.
Serum melatonina and urinary 6-methoxymelatonin in major depression.
Psychoneuroendocrinology, 29 (2004), pp. 1-12
[37.]
O. Van Reeth, S. Maccari.
Biology of circadian rhythms: possible links to the pathophysiology of human depression.
Medicographia, 29 (2007), pp. 17-21
[38.]
S. Yous, J. Andrieux, H.E. Howell, P.J. Morgan, P. Renard, B. Pfeiffer, et al.
Novel naphtalenic ligands with high affinity for the melatonin receptor.
J Med Chem, 35 (1992), pp. 1484-1486
[39.]
V. Audinot, F. Mailliet, C. Lahaye-Brasseur, A. Bonnaud, A. Le Gall, C. Amossé, et al.
New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedeberg's.
Arch Pharmacol, 367 (2003), pp. 553-561
[40.]
M.J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, et al.
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxy-tryptamine 2C receptors, blockade of wich enhances the activity of frontocortical dopaminergic and adrenergic pathways.
J Pharmacol Exp Ther, 306 (2003), pp. 954-964
[41.]
M. Bourin, E. Mocaer, R. Porsolt.
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimmming test in rodents: involvement of melatonin and serotonin receptors.
J Psychiatr Neurosci, 29 (2004), pp. 126-133
[42.]
S.W. Ying, B. Rusak, P. Delagrange, E. Mocaer, P. Renard, B. Guardiola-Lemaitre.
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.
Eur J Pharmacol, 296 (1996), pp. 33-42
[43.]
R.M. Buijs, A. Kalsbeek.
Hypothalamic integration of central and peripheral clocks.
Nat Rev Neurosci, 2 (2001), pp. 521-526
[44.]
E. Fuchs, M. Simon, B. Schmelting.
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Int Clin Psychopharmacol, 21 (2006), pp. S17-S20
[45.]
A. Chagraoui, P. Protais, T. Filloux, E. Moca.
Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.
Psychopharmacology, 170 (2003), pp. 17-22
[46.]
C. Álamo, E. Cuenca, F. López-Muñoz.
Iatrogenia medicamentosa: reacciones adversas a los psicofármacos.
Tratado de Psiquiatría, pp. 1875-1900
[47.]
M.J. Millan, F. Lejeune, A. Gobert.
Reciprocal autoreceptor and heteroreceptor control of serotonergic dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents.
J Psychopharmacol, 14 (2000), pp. 114-138
[48.]
Stein DJ, Ahokas A, Fabiano A. Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled study. Poster presented at 20th European College of Neuropsychopharmacology (ECNP) Congress, Vienna; 2007. p. 13-7.
[49.]
M.J. Millan, M. Brocco, A. Gobert, A. Dekeyne.
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5HT2C receptor blockade.
Psychopharmacology, 177 (2005), pp. 1-12
[50.]
S. Das, L. Tecott.
Diminished anxiety-Iike responses in 5-HT 2C receptor mutant mice.
Soc Neurosci Abstr, 22 (1996), pp. 811-812
[51.]
E. Cuenca, C. Alamo, F. López-Muñoz.
Perfil ansiolítico de los fármacos antidepresivos.
Psiquiatr Biol, 5 (1998), pp. 12-21
[52.]
L. Martinet, B. Guardiola-Lemaitre, E. Mocaer.
Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent.
Pharmacol Biochem Behav, 54 (1996), pp. 713-718
[53.]
S.M. Armstrong, O.M. McNulty, B. Guardiola-Lemaitre, J.R. Redman.
Properties of the melatonin agonist S 20098 (agomelatine) and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).
Pharmacol Biochem Behav, 46 (1993), pp. 45-49
[54.]
J.R. Redman, B. Guardiola-Lemaitre, M. Brown, P. Delagrange, S.M. Armstrong.
Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms.
Psychopharmacology (Berlin), 118 (1995), pp. 385-390
[55.]
B. Pitrosky, R. Kirsch, A. Malan, E. Mocaer, P. Pevet.
Organisation of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist.
Am J Physiol, 277 (1999), pp. R812-R828
[56.]
K. Kräuchi, C. Cajochen, D. Möri, P. Graw, A. Wirz-Justice.
Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature.
Am J Physiol Integr Comp Psysiol, 41 (1997), pp. R1176-R1186
[57.]
O. Van Reeth, L. Weibel, E. Olivares, S. Maccari, E. Mocaer, F.W. Turek.
Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus.
Am J Physiol Regul Integr Comp Physiol, 280 (2001), pp. R1582-R1591
[58.]
R. Leproult, A. Van Onderbergen, M. L’Hermite-Baleriaux, E. van Cauter, G. Copinschi.
Phase-shifts on 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.
Clin Endocrinol, 63 (2005), pp. 298-304
[59.]
M. Popoli.
Agomelatine innovative pharmacological approach in depression.
CNS Drugs, 23 (2009), pp. 27-34
[60.]
M. Zupancic, C. Guilleminault.
Agomelatine. A preliminary review of a new antidepressant.
CNS Drugs, 20 (2006), pp. 981-992
[61.]
M. Papp, P. Gruca, P.A. Boyer, E. Mocaër.
Effect of agomelatine in the chronic mild stress model of depression in the rat.
Neuropsychopharmacology, 28 (2003), pp. 694-703
[62.]
V. Bertaina-Anglade, C. Drieu La Rochelle, P. Boyer, E. Mocaer.
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.
Behav Pharmacol, 17 (2006), pp. 703-713
[63.]
Álamo C, López-Muñoz F, García-García P. Trastornos del estado de ánimo. En: Principios de fisiopatología para la atención farmacéutica. Módulo IV. Plan Nacional de Formación Continuada. Consejo General de Colegios Oficiales de Farmacéuticos. 2009;5:97-138.
[64.]
E. Fuchs, S. Corbach-Söhle, B. Schmelting, E. Mocaer, M.J. Millan, C. Gabriel-Gracia.
Effects of agomelatine and S32006, a selective 5HT2C receptor antagonist, in chronically-stressed tree shrews European Neuropsychopharmacology.
The Journal of the European College of Neuropsychopharmacology, 18 (2008), pp. S348
[65.]
P. Gressens, L. Schwendimann, I. Husson, G. Sarkozy, E. Mocaer, J. Vamecq, et al.
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.
Eur J Pharmacol, 588 (2008), pp. 58-63
[66.]
G. Bonanno, R. Giambelli, L. Raiteri, E. Tiraboschi, S. Zappettini, L. Musazzi, et al.
Chronic antidepressants reduce depolarizationevoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus.
J Neurosci, 25 (2005), pp. 3270-3279
[67.]
M. Mallei, S. Zappettini, L. Musazzi, E. Mocaer, C. Gabriel, M. Milanese, et al.
Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5-HT2C properties.
Eur Neuropsychopharmacol, 19 (2009), pp. S441
[68.]
A. Soumier, S. Lortet, C. Gabriel, E. Mocaer, M.J. Millan, A. Daszuta.
Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine.
Eur Neuropsychopharmacol, 18 (2008), pp. S350
[69.]
F. Calabrese, R. Molteni, S. Pisoni, C. Gabriel, E. Mocaer, G. Racagni, et al.
Synergic mechanisms in the modulation of BDNF and Arc following agomelatine administration. European Neuropsychopharmacology.
The Journal of the European College of Neuropsychopharmacology, 19 (2009), pp. S442
Copyright © 2010. Sociedad Española de Psiquiatría and Sociedad Española de Psiquiatría Biológica